U.S. biopharmaceutical companies to benefit from Almac's European Product Launch workshop

Almac is hosting its inaugural European Product Launch workshop in Boston, MA on 17th May 2011. Targeted specifically at the biopharmaceutical sector, the workshop provides consultative advice and services to US companies to successfully launch drug products onto the European market.

The workshop will provide US companies with important market and regulatory framework knowledge, whilst guiding them through the European product launch process right through from submitting an MAA to final distribution of drug products to end-users.

Attendees will also learn from the real life experiences of three of Almac's many US clients who have successfully launched drug products into the European marketplace including: Eisai Inc, Millennium: The Takeda Oncology Company and The Medicines Company.

Ian Markwell, VP of Quality for Almac's Pharma Services business unit commented 'This workshop provides a significant opportunity for US companies to learn first hand of the processes of launching product into Europe, as many companies based outside the EU, find the European regulatory and quality framework complex.'

One of the key presenters at the workshop Ms Trudy Burke, Senior Director, Baltimore & Gliadel Operations, Eisai Inc remarked: 'I am delighted to share my experience of partnering with Almac, while helping to advise US companies on the challenges of launching a high value, temperature sensitive product in Europe.'

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.